Oxybutynin Tablet, Film Coated, Extended Release
Product Images NDC 0615-8220

The text is describing the results of a study that compares the efficacy of oxybutynin chloride extended release tablets to placebo in reducing the number of urge urinary incontinence episodes per week. The first section presents data on the mean change in the number of episodes from baseline for both the oxybutynin chloride and placebo groups, as well as the confidence interval for the difference between the two groups. The second section presents similar data from another study and notes that the difference between oxybutynin chloride and placebo was statistically significant. The data presented also notes that the mean was adjusted for missing observations and set to baseline values.*

This is a study comparing the efficacy of Oxybutynin Chloride extended-release tablets versus a placebo. The study tracks the change from baseline in episodes per week of urinary incontinence in patients taking either Oxybutynin or a placebo. The study also notes a difference in efficacy between Oxybutynin and a fluid form of the drug. There is mention of variance adjustment for missing observations.*

This is a package of Oxybutynin Chloride extended-release tablets with a 10mg dose, manufactured by Cadila for Zydus. The package contains 30 tablets, and it is meant for institutional use only. The tablets come in a tightly sealed container that must be protected from moisture and humidity. The lot number is 8220-, and the expiration date is not available. The package insert or label should be consulted for dosage information.*